BAT1706 vs HLX04

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

BAT1706 · Avzivi

Marketed by Bio-Thera Solutions and partners

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03329911 · Phase 3 · completed

This double-blind, randomized Phase 3 trial compared BAT1706, a proposed bevacizumab biosimilar, with EU-sourced Avastin, each with paclitaxel and carboplatin, in 651 patients with advanced non-squamous non-small cell lung cancer. The primary endpoint was overall response rate at week 18, tested for equivalence against pre-specified margins (risk ratio 0.75 to 1.33 or 0.73 to 1.36; risk difference -0.12 to 0.15). Both the risk ratio (1.08, 90% CI 0.94 to 1.24) and the risk difference (0.03, 95% CI -0.04 to 0.11) fell inside the margins, so the equivalence primary was met. Source: the peer-reviewed paper (Cancer Med 2023).

Reported efficacy

Overall Response Rate (Week 18): Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023). (met)

Result source: NCT03329911

HLX04 · Hanbeitai

Marketed by Shanghai Henlius Biotech

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03952403 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.

Reported efficacy

Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. (mixed)

Result source: NCT03952403

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT1706HLX04
PFS, median—Not posted · NCT03329911—Not reported
OS, median—Not posted · NCT03329911—Not reported
ORR—Not posted · NCT03329911—Not reported
Duration of response, median—Not posted · NCT03329911—Not reported

PFS, median

BAT1706
—Not posted · NCT03329911
HLX04
—Not reported

OS, median

BAT1706
—Not posted · NCT03329911
HLX04
—Not reported

ORR

BAT1706
—Not posted · NCT03329911
HLX04
—Not reported

Duration of response, median

BAT1706
—Not posted · NCT03329911
HLX04
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HLX04
ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. NCT03952403 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BAT1706: 3 of 4 rows · HLX04: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBAT1706
Dropout rate
31.7%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Serious AEs
36.6%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
musculoskeletal and connective tissue disorders 1.5%
renal and urinary disorders 0.9%
hepatobiliarydisorders 0.3%
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BAT1706

ORR 44.6% (n=325) vs 47.9% (n=326) EU Avastin® @ 18wk
event count · % of participants
NCT03329911 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 · converted to % from 145 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1706's landscape · HLX04's landscape